IL6ST抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P02446(IL6ST Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The IL6ST antibody targets the interleukin-6 signal transducer (IL6ST), also known as gp130. a key component of the receptor complex for IL-6 and related cytokines (e.g., IL-11. CNTF, LIF). As a shared signaling subunit, gp130 mediates downstream activation of JAK/STAT, MAPK, and PI3K pathways, influencing processes like inflammation, immune regulation, and cell survival. Dysregulation of gp130 is linked to chronic inflammatory diseases (e.g., rheumatoid arthritis), cancers, and autoimmune disorders, making it a therapeutic and diagnostic focus.

IL6ST antibodies are essential tools for studying gp130 expression, localization, and function in research. They enable detection of gp130 in assays like Western blotting, immunohistochemistry, and flow cytometry, aiding investigations into cytokine signaling mechanisms. Therapeutic antibodies targeting IL6ST or its associated pathways aim to modulate hyperactive signaling in diseases. For example, inhibitors blocking IL-6/gp130 interactions are explored for cancer and inflammatory conditions. However, challenges remain in balancing efficacy and safety due to gp130's broad physiological roles.

In summary, IL6ST antibodies serve as critical reagents for both basic research and drug development, offering insights into cytokine biology and pathways relevant to multiple diseases.